uniQure (NASDAQ:QURE) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of uniQure (NASDAQ:QURE) from a hold rating to a sell rating in a research report released on Sunday morning.

Other equities analysts have also recently issued research reports about the company. Benchmark reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. The Goldman Sachs Group lowered their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Stifel Nicolaus cut their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. Finally, Wells Fargo & Company cut their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $60.82.

uniQure Price Performance

Shares of QURE opened at $21.50 on Friday. The stock has a market cap of $1.34 billion, a PE ratio of -4.90 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. uniQure has a 1-year low of $7.76 and a 1-year high of $71.50. The firm has a fifty day moving average price of $25.06 and a 200 day moving average price of $27.73.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. As a group, sell-side analysts anticipate that uniQure will post -3.75 EPS for the current year.

Insider Transactions at uniQure

In other uniQure news, Director Robert Gut sold 31,434 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the completion of the transaction, the director directly owned 40,145 shares in the company, valued at approximately $1,094,352.70. The trade was a 43.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jack Kaye sold 6,390 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 76,634 shares of company stock valued at $2,208,705. Insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Private Trust Co. NA purchased a new stake in uniQure during the third quarter valued at about $28,000. Jones Financial Companies Lllp raised its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the period. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the 3rd quarter valued at about $50,000. FNY Investment Advisers LLC grew its holdings in shares of uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares during the period. Finally, Knott David M Jr purchased a new stake in shares of uniQure during the 3rd quarter worth about $117,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure refreshed its corporate presentation to highlight pipeline priorities and its regulatory outlook, aiming to clarify program timelines and commercial positioning — a constructive step for investors who want clearer milestones. uniQure updates gene therapy pipeline and regulatory outlook
• Neutral Sentiment: Several recent pieces reassess uniQure’s valuation given recent volatility and progress in its gene‑therapy programs; these analyses outline upside scenarios but also note execution and regulatory risk, so they provide context rather than an immediate catalyst. Assessing uniQure (QURE) Valuation After Recent Volatility And Gene Therapy Progress
• Negative Sentiment: Investors sold following the company’s pivotal FDA Type A meeting on AMT‑130; coverage indicates market reaction was cautious to the meeting outcome, increasing near‑term uncertainty around the HD program’s regulatory path. How Investors Are Reacting To uniQure (QURE) After Its Pivotal FDA Type A Meeting On AMT-130
• Negative Sentiment: An insider, director Jack Kaye, sold 6,390 shares in early January (avg. ~$27.28), a sizable reduction in his position that can be read negatively by the market even if not uncommon for insiders to trim holdings. Jack Kaye Sells 6,390 Shares of uniQure (NASDAQ:QURE) Stock
• Negative Sentiment: Short interest jumped in December to roughly 11.99M shares (about 20.2% of float) with a short‑interest ratio near 4.4 days — elevated wet‑paint for downside pressure and volatility if negative news or headlines continue. (summary of recent short‑interest reports)
• Negative Sentiment: A law firm has issued an investigation notice (Kessler Topaz) regarding potential securities claims tied to uniQure, which can amplify selling pressure and uncertainty for some investors. QURE Investigation Reminder: Kessler Topaz Meltzer & Check

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.